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Background: Current non-biodegradable polymers used in drug eluting stents are thought to be a potential cause of late-stage thrombosis. The 
purpose of this study was to compare the biocompatibility of novel biodegradable poly (d, l-lactide -co-glycolide)/amorphous calcium phosphate 
(PLGA/ACP) copolymer with existing nonbiodegradable poly(ethylene-co-vinyl acetate)/poly(n-butyl methacrylate) (PEVA/PBMA) copolymer 
(bioabsorbable) in a rat aorta stenting model at both one month and three months periods.
Methods: A total of 39 metal stents (316L stainless steel, 13mm), coated with either PEVA/PBMA copolymer (n=13), PLGA/ACP copolymer (n=18) 
and PLGA only (n=8) (average polymer loading were 260μg±10% with coating thickness of 30±10μm) were implanted into 39 Sprague-Dawley rats 
aortas via iliac arterial insertion. Rats were sacrificed at one month (PEVA/PBMA n=5, PLGA/ACP n=10 and PLGA, n=6) and three months (PEVA/
PBMA n=5; PLGA/ACP: n=4) and the stented arteries were harvested with morphometric and immunohistochemical analysis.
Results: There was no significant difference in acute thrombosis (rat died or was paralyzed within 24 hours due to thrombosis in stented aorta) 
among all study groups (PEVA/PBMA 3/13;23%, PLGA/ACP 4/18;22% and PLGA 2/8;25%, p=0.27). At one month post implantation, the percentage 
of restenosis and arterial inflammation scores were significantly higher in PLGA only group than that in both PEVA/PBMA and PLGA/ACP (restenosis 
score: PLGA 53±6%, PEVA/PBMA 33±6%, PLGA/ACP 32±4%; p=0.01, inflammatory score: PLGA 1.6±0.5, PEVA/PBMA 1.2±0.3, PLGA/ACP 1.2±0.4; 
p=0.04). At three months, although there were no significant differences in the rate of restenosis between two study groups (PEVA/PBMA vs PLGA/
ACP), the PEVA/PBMA coated stent had an increased incidence (40%) of neointimal necrosis, with inflammatory cell infiltration.
Conclusions: These data suggest that a PLGA/ACP copolymer coated stent has better biocompatibility than both PLGA and PEVA/PBMA polymers 
and is a potential bioabsorbable polymer platform for drug eluting stent application without any adverse effect on restenosis.
